Bio-Synthesis Awarded NIH Grant to Develop Synergistic Adjuvants that
Stimulate both Innate and Adaptive Immunities
BioSynthesis announces the award of a two-year phase I SBIR grant by NIH to further its
development program of immune agonists. These new agents have in their chemical structure
different determinants that stimulate both innate and acquired immunity, leading to synergistic
effects on the immune response. These new immune agonists could be useful in the development of
difficult vaccines such as HIV-1 and cancer vaccines.
Lewisville, TX, March 09, 2010 --(PR.com)-- Bio-Synthesis, Inc. announced today that the National
Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), has
awarded the company a 2-year, $590,000, Small Business and Innovation Research (SBIR) Phase 1 grant.
The company will use the proceeds to further the development of its proprietary adjuvants or immune
agonists that carry in a single molecule the various determinants needed to stimulate both innate and
adaptive immunities, causing synergistic effects on T cell immunity. This synergism may stimulate an
exceptional Th1 immune response with production of cytotoxic T lymphocytes (CTLs), which would be
advantageous in preventive vaccines against infectious agents like HIV-1. Because of their structure,
these compounds may reverse the immune tolerance associated with aging and other conditions like
malnutrition; as part of the formulation of therapeutic vaccines, they could be useful in stimulating an
immune response medically effective in the treatment of certain chronic infectious diseases, such as
HIV-1 and hepatitis viruses B and C. Due to their ameliorative effects of tolerance, these novel agonists
may have applications in therapeutic vaccines against cancer, a group of diseases closely associated with
Although the HIV-1 antigens required for an effective vaccine have been identified, this virus unusually
high virulence has precluded so far the development of an effective vaccine.